Microbix Biosystms (MBX) Earnings Dates, Call Summary & Reports

Q: When does Microbix Biosystms J (TSE:MBX) report earnings?

Microbix Biosystms J (TSE:MBX) is schdueled to report earning on May 14, 2026, TBA (Confirmed).

Q: What is Microbix Biosystms J (TSE:MBX) earnings time?

Microbix Biosystms J (TSE:MBX) earnings time is at May 14, 2026, TBA (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Compare

37 Followers

Earnings Data

Report Date

May 14, 2026

TBA (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

―

Last Year’s EPS

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:Feb 12, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

The call mixes clear operational and strategic progress (sequential revenue growth, QAPs expansion, recombinant antigen commercialization, new client wins including the College of American Pathologists, improved cash collection, active share repurchases, and favorable Kinlytic FDA interactions) with material near-term financial challenges (a ~30% year-over-year revenue decline driven by a 49% drop in antigen sales due to China distributor inactivity, depressed gross margins from lower volumes, a Q1 net loss of $1.2M, and quarter-end receivable timing issues). Management framed the setbacks as tactical and emphasized diversification and efficiency gains to reduce volatility and restore margins as volumes scale.

Company Guidance

Management guided that breakeven is expected once quarterly revenues exceed in excess of $5.5M (management targets roughly $5.5–$6.0M per quarter) and that they are modeling full‑year fiscal 2026 revenues about 30% above the 2025 trough (roughly $18–$19M); Q1 actuals were $4.2M (up 13% sequentially, down ~30% YoY) with a controlled net loss of $1.2M, QAPs revenue of $1.9M (up 15% YoY) and antigen sales down 49% YoY largely due to a >$2M shortfall from the China distributor, gross margins compressed but should improve as revenues scale, operating expenses were at/below expectations (Q1 seasonally lower but expected to rise in Q2/Q3), accounts receivable more than doubled at quarter end (management collected $3.3M in January), cash was $10.6M at end‑January (up $1.5M from December), inventory held steady, allowance for doubtful accounts ~$35k, NCIB repurchases totaled ~700k shares (~$175k) in Q1 and ~1M shares to date with a current buyback pace of 15,000 shares/day (maximum daily allowance 20,339; ~3.75M/year at 15k/day), Kinlytic sBLA timing is targeted in late 2027, and recombinant antigen commercialization (first product: SARS‑CoV‑2 capsid) is now driving supply‑chain security and margin improvement.

Sequential Revenue Growth

Q1 fiscal 2026 revenue of $4.2M, up 13% sequentially from the prior quarter and reported as in line with budget expectations.

QAPs (PT/EQA) Business Expansion

QAPs revenue of $1.9M, a 15% improvement year-over-year; management noted QAPs are a growing and more broadly distributed portion of revenues, reducing customer concentration risk.

Antigen Business (Excluding China) Recovery

Management stated that excluding the China distributor shortfall, the remainder of the antigen business was up about 5% quarter-over-quarter.

Improved Cash Position and Collections

Collected $3.3M in January leading to a cash balance of $10.6M at end of January (up $1.5M from end of December), demonstrating working capital recovery after quarter-end receivable buildup.

Commercialization of Recombinant Antigens

Onboarded recombinant antigen capabilities and launched first commercial recombinant product (SARS‑CoV‑2 viral capsid antigen) now used in Microbix QAPs and products — expected to strengthen supply chain and improve margins going forward.

New Client Wins and Market Expansion

Disclosed new client programs in molecular pathology and point-of-care genetics; announced relationships with Sekisui (U.S. point-of-care) and Seegene (Mexico cervical cancer screening) and added the College of American Pathologists as a customer (expected to be six-figure in 2026 with potential to be a meaningful seven-figure account over time).

Operational Improvements and Cost Efficiencies

Reported improvements in manufacturing throughput, yields, reduced testing burden, and increased use of electronic quality management systems which are expected to reduce production costs and improve margins as volumes ramp.

Therapeutics Program (Kinlytic) Progress and Favorable FDA Interaction

Kinlytic program proceeding with Sequel; FDA feedback described as uncontroversial regarding modernization and replacement of animal-derived components; parallel drug substance/product development ongoing with an sBLA target in late 2027.

Active Share Buyback Program

NCIB renewed; repurchased ~700,000 shares in Q1 and ~1,000,000 shares to date, currently buying back at 15,000 shares/day (well below the daily maximum), signalling management confidence and an anti-dilution stance.

Microbix Biosystms (TSE:MBX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:MBX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 14, 2026	2026 (Q2)	- / -	0	―	―	―
Feb 12, 2026	2026 (Q1)	- / >-0.01	0.006	-233.33% (-0.01)		―
Dec 18, 2025	2025 (Q4)	- / -0.01	0.003	-466.67% (-0.01)	―	―
Aug 14, 2025	2025 (Q3)	- / -0.01	0.002	-700.00% (-0.01)	―	―
May 15, 2025	2025 (Q2)	- / 0.00	0.003	―	―	―
Feb 13, 2025	2025 (Q1)	- / <0.01	0.018	-66.67% (-0.01)	―	―
Dec 19, 2024	2024 (Q4)	- / <0.01	0.014	-78.57% (-0.01)	―	―
Aug 14, 2024	2024 (Q3)	- / <0.01	-0.006	133.33% (<+0.01)	―	―
May 15, 2024	2024 (Q2)	- / <0.01	0	―	―	―
Feb 14, 2024	2024 (Q1)	- / 0.02	-0.009	300.00% (+0.03)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:MBX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 12, 2026	C$0.23	C$0.23	-2.17%
Dec 18, 2025	C$0.24	C$0.21	-12.50%
Aug 14, 2025	C$0.28	C$0.24	-12.50%
May 15, 2025	C$0.36	C$0.34	-5.56%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Microbix Biosystms J (TSE:MBX) report earnings?

Microbix Biosystms J (TSE:MBX) is schdueled to report earning on May 14, 2026, TBA (Confirmed).

What is Microbix Biosystms J (TSE:MBX) earnings time?

Microbix Biosystms J (TSE:MBX) earnings time is at May 14, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:MBX EPS forecast?

Currently, no data Available